obinutuzumab,ibrutinib,venetoclax
abbvie,roche,janssen
['cll', 'venetoclax', 'obinu', 'leukemia', 'ibru']
patients with treatment-na ve chronic lymphocytic leukemia who were treated with venetoclax and obinutuzumab with or without ibrutinib experienced a progression-free survival benefit compared with standard chemoimmunotherapy. #cll #eha2022 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.